ArticleClinical endocrinology2026
Parathyroid Carcinoma Revisited: Clinical and Pathological Insights From Two Decades of Experience.
Article in Clinical endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParathyroid carcinoma is a rare endocrine malignancy (< 1% of primary hyperparathyroidism and 0.005% of all cancers) that often mimics a benign adenoma, leading to diagnosis only after surgery, unless invasion or metastasis is present.
objectiveTo identify distinguishing clinical, biochemical and pathological features of parathyroid carcinoma in comparison with primary parathyroid adenoma and atypical parathyroid tumor and to determine its perioperative predictors.
methodsA retrospective analysis compared 16 histopathologically confirmed parathyroid carcinoma cases with 378 primary parathyroid adenoma and 11 atypical parathyroid tumors, evaluating and contrasting their clinical and laboratory features.
resultsNo significant differences in age or gender were observed across groups. Parathyroid carcinoma was significantly associated with hoarseness, hypercalcaemic crisis, palpable neck mass (all p < 0.001), pancreatitis, and concomitant bone/kidney involvement (both p < 0.05). Ridge-penalized logistic regression identified hoarseness, palpable neck mass and an involved parathyroid gland weight ≥ 3 grams (g) as significant perioperative predictors of parathyroid carcinoma while adenoma diameter, serum calcium levels and intact parathyroid hormone (iPTH) were not statistically significant. ROC analysis showed parathyroid adenoma weight of ≥ 7.5 g had the highest diagnostic accuracy (75% sensitivity, 86% specificity), whereas serum calcium and iPTH exhibited only moderate diagnostic performance. Recurrence was observed in 31% of cases.
conclusionParathyroid carcinoma exhibits more severe clinical and biochemical features and greater gland weight than benign lesions. The high recurrence rate necessitates rigorous long-term surveillance. While offering a framework for preoperative risk stratification, these retrospective findings require prospective validation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.